Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeuroSearch's development and license partner Abbott has initiated a phase II study with the drug candidate, ABT-894, for the treatment of attention deficit-hyperactivity disorder in adults.
Subscribe to our email newsletter
The clinical phase II study is a dose-ranging trial to evaluate the efficacy of ABT-894 in attention deficit-hyperactivity disorder (ADHD) patients. The first patients have been enrolled and dosed in the study.
ABT-894 is a subtype selective modulator of Neuronal Nicotinic Acetylcholine receptors (NNR), which had promising effects in preclinical models for pain and other central and peripheral nervous system diseases.
It has successfully completed a number of phase I single and multiple dosing studies. An additional clinical phase II program with ABT-894 is planned in patients suffering from diabetic neuropathy.
Under the terms of the license agreement, Abbott is responsible for the clinical development and commercialization of ABT-894 and will finance all development costs. NeuroSearch will receive milestone payments as well as royalties on sales.